Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene’s Otezla Grabs New Psoriatic Arthritis Patients As Launch Accelerates

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene reports its apremilast is attracting more new psoriatic arthritis patients than branded leaders in the space. Sales for its first full quarter amounted to $18 million and new indication in psoriasis should start to contribute later this year, company says.

You may also be interested in...



Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label

Celgene estimates 80% of moderate-to-severe plaque psoriasis patients experience the disease in their scalps, meaning positive data in this indication could broaden the market opportunity for Otezla substantially. Novartis’ Cosentyx got scalp psoriasis added to its US label in February.

Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline

The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.

Celgene Dips Into The Antibody Well Once More, Partners With Sutro

Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel